Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

Change in Truncal fat percentage was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Truncal fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Truncal fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Truncal lean body mass was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Truncal lean body mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Total fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in total fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Visceral adipose tissue was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Visceral adipose tissue was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Android fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Android fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Gynoid fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Gynoid fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Appendicular skeletal muscle mass was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Appendicular skeletal muscle mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Lean body mass was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Lean body mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Bone mineral content was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Bone mineral density was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in insulin-like growth factor (IGF-I) standard deviation scores (SDS) was measured from baseline (week -3) until the end of the main treatment period (week 34). A higher score reflects a better outcome.

Change in IGF-I SDS was measured from baseline (week -3) until the end of the extension treatment period (week 87). A higher score reflects a better outcome.

Change in insulin like growth factor binding protein 3 (IGFBP 3) SDS was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in IGFBP 3 SDS was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in treatment-related impact measure - adult growth hormone deficiency (TRIM-AGHD) scores (total and domain scores) was measured from baseline (week 0) until the end of the main treatment period (week 34). The TRIM-AGHD questionnaire measured the impact of GH treatment on the functioning and well-being of AGHD patients. The 4 concepts covered by the questionnaire were physical health, energy levels, cognitive ability and psychological health. TRIM-AGHD has 27 items and a total score as well as domain specific scores can be derived. The total score includes all answers that has been used to calculate each of the 4 subdomains. The score ranged from 0 to 100 for 'individual domains' and for the 'total', where a lower score reflected a better outcome.

Change in TRIM-AGHD (total and domain scores) was measured from baseline (week 0) until the end of the extension treatment period (week 87). The TRIM-AGHD questionnaire measured the impact of GH treatment on the functioning and well-being of AGHD patients. The 4 concepts covered by the questionnaire were physical health, energy levels, cognitive ability and psychological health. TRIM-AGHD has 27 items and a total score as well as domain specific scores can be derived. The total score includes all answers that has been used to calculate each of the 4 subdomains. The score ranged from 0 to 100 for 'individual domains' and for the 'total', where a lower score reflected a better outcome.

SF-36v2™ questionnaire measured health-related quality of life (HRQoL) on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (higher scores indicates better HRQoL) from SF-36 were converted to norm-based scores to enable a direct interpretation in relation to distribution of the scores in the 2009 U.S. general population. Mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. Physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.

SF-36v2™ questionnaire measured health-related quality of life (HRQoL) on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (higher scores indicates better HRQoL) from SF-36 were converted to norm-based scores to enable a direct interpretation in relation to distribution of the scores in the 2009 U.S. general population. Mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. Physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.

Scores from the TSQM-9 scale were calculated at the end of the main treatment period (week 34). The Treatment Satisfaction Questionnaire for Medication - 9 items (TSQM-9) is a generic questionnaire that measures a patients' satisfaction with medication. Items are rated on a 5-point or 7-point scale according to patients' experience with the medication. The items covered are satisfaction with the effect of the medication, convenience and global treatment satisfaction. Each domain is based on 3 questions. The score is calculated in a range from 0 to 100, where a higher score reflects a better outcome. Scores have been summed and then scaled to 0-100.

Scores from the TSQM-9 scale were calculated at the end of the extension treatment period (week 87). The Treatment Satisfaction Questionnaire for Medication - 9 items (TSQM-9) is a generic questionnaire that measures a patients' satisfaction with medication. Items are rated on a 5-point or 7-point scale according to patients' experience with the medication. The items covered are satisfaction with the effect of the medication, convenience and global treatment satisfaction. Each domain is based on 3 questions. The score is calculated in a range from 0 to 100, where a higher score reflects a better outcome. Scores have been summed and then scaled to 0-100.

Change in Total cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Total cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in High-density lipoprotein (HDL) cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in HDL-cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Low-density lipoprotein (LDL) cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in LDL-cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Triglycerides was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Triglycerides was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in high-sensitivity C-reactive protein (hs-CRP) was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in hs-CRP was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Interleukin 6 (IL-6) was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in IL-6 was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in body weight was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in body weight was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in waist circumference was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in waist circumference was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Number of adverse events from baseline (week 0) until the end of week 35 were reported. This endpoint shows number of treatment-emergent adverse events (TEAEs), including the injection site reactions.

Number of adverse events from baseline (week 0) until the end of week 88 were reported. This endpoint shows the number of TEAEs along with the injection site reactions.

Number of participants with anti-NNC0195-0092 antibodies at week 35 was recorded. The numbers presented in this endpoint are the participants that were found to have positive antibodies.

Number of participants with anti-NNC0195-0092 antibodies at week 88 was recorded. The numbers presented in this endpoint are the participants that were found to have positive antibodies.

Incidence of technical complaints were recorded from baseline (week 0) until week 35.

Incidence of technical complaints were recorded from baseline (week 0) until week 88.

Change in physical examination from baseline (week 0) until the end of the main treatment period (week 35) was reported. Results are presented for the following examinations: 1) Head, neck, eyes and nose 2) Respiratory system (sys.) 3) Cardiovascular sys. 4) Gastrointestinal sys. 5) Musculoskeletal sys. 6) Central \& Peripheral nervous sys. 7) Skin 8) Lymph node palpation

Change in physical examination from baseline (week 0) until the end of the extension period (week 88) was reported. Results are presented for the following examinations: 1) Head, neck, eyes and nose 2) Respiratory system (sys.) 3) Cardiovascular sys. 4) Gastrointestinal sys. 5) Musculoskeletal sys. 6) Central \& Peripheral nervous sys. 7) Skin 8) Lymph node palpation

Change in Electrocardiogram (ECG) evaluation from baseline (week -3) until the end of the main treatment period (week 35) was reported.

Change in ECG evaluation from baseline (week 0) until the end of the extension period (Week 88) was reported.

Change in diastolic blood pressure was measured from baseline (week -3) until the end of the main treatment period (week 35).

Change in diastolic blood pressure was measured from baseline (week -3) until the end of the extension treatment period week 88.

Change in systolic blood pressure was measured from baseline (week -3) until the end of the main treatment period (week 35).

Change in systolic blood pressure was measured from baseline (week -3) until the end of the extension treatment period (week 88).

Change in pulse was measured from baseline (week -3) until the end of the main treatment period (week 35).

Change in pulse was measured from baseline (week -3) until the end of the extension treatment period (week 88).

Change in Haemoglobin was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Haemoglobin was measured from baseline (week -3) until the end of the week 87.

Change in Haematocrit was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Haematocrit was measured from baseline (week -3) until the end of the week 87.

Change in Erythrocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Erythrocytes was measured from baseline (week -3) until the end of the week 87.

Change in Mean corpuscular volume (MCV) was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Mean corpuscular volume (MCV) was measured from baseline (week -3) until the end of the week 87.

Change in Mean corpuscular haemoglobin concentration (MCHC) was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Mean corpuscular haemoglobin concentration (MCHC) was measured from baseline (week -3) until the end of the week 87.

Change in Thrombocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Thrombocytes was measured from baseline (week -3) until the end of the week 87.

Change in Leucocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Leucocytes was measured from baseline (week -3) until the end of the week 87.

Change in ALT was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in ALT was measured from baseline (week -3) until the end of the week 87.

Change in Albumin was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Albumin was measured from baseline (week -3) until the end of the week 87.

Change in Alkaline phosphatase (ALP) was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Alkaline phosphatase (AP) was measured from baseline (week -3) until the end of the week 87.

Change in AST was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in AST was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Bilirubin was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Bilirubin was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Calcium was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Calcium was measured from baseline (week -3) until the end of the week 87.

Change in Chloride was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Chloride was measured from baseline (week -3) until the end of the week 87.

Change in Creatinine was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Creatinine was measured from baseline (week -3) until the end of the week 87.

Change in Creatine kinase was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Creatine kinase was measured from baseline (week -3) until the end of the week 87.

Change in GGT was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in GGT was measured from baseline (week -3) until the end of the week 87.

Change in Phosphate (inorganic) was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Phosphate (inorganic) was measured from baseline (week -3) until the end of the week 87.

Change in Potassium was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Potassium was measured from baseline (week -3) until the end of the week 87.

Change in Sodium was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Sodium was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in total protein was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in total protein was measured from baseline (week -3) until the end of extension treatment period (week 87).

Change in Urea was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Urea was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Uric acid was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Uric acid was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Estimated GFR creatinine (CKD-EPI) was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in estimated GFR creatinine (CKD-EPI) was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Fasting plasma glucosewas measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Fasting plasma glucose was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Fasting insulin was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Fasting insulin was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in steady state beta cell function (%B) was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in steady state beta cell function (%B) was measured from baseline (week -3) until the end of the week 87.

Change in Insulin resistance (IR %) was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Insulin resistance (IR %) was measured from baseline (week -3) until the end of the extension treatment period (week 87).

Change in Glycated haemoglobin (HbA1c) (%) was measured from baseline (week -3) until the end of the main treatment period (week 34).

Change in Glycated haemoglobin (HbA1c) was measured from baseline (week -3) until the end of the extension treatment period (week 87).